Alexander (Alex) Thompson

“I guess you've now had futility analyses that have discontinued programs in Sjogren's and TED. I guess looking forward, should we assume that all your pivotals have built-in futility analyses as we think about data next year in CIDP for Empath CiproBart, and potentially later for EFGAR, Tigamon, and Graves?”

“You know, going back to the questions around placebo responses, you know, how are you thinking about managing placebo response in the GRADE studies, particularly in the backdrop of ATT down titration and the potential for, you know, waxing and waning of disease in that context over longer periods of time?”

“You know, maybe another one, Nell, I'm not sure you will answer, but I just wanted to ask about, you know, you've had a lot more experience now dosing patients to 16 weeks plus across AD and asthma.”

“Maybe shifting gears just before Brutinib, the parasol group is now looking at membranous nephropathy, and there's a workshop later in September. I guess, like, based on the FSGS experience here, you know, what could be the potential outcome in membranous dipropathy with parasol?”